KR20240016938A - 포스포이노시티드 3 키나아제 베타 억제제 및 그 조성물 및 방법 - Google Patents
포스포이노시티드 3 키나아제 베타 억제제 및 그 조성물 및 방법 Download PDFInfo
- Publication number
- KR20240016938A KR20240016938A KR1020237029259A KR20237029259A KR20240016938A KR 20240016938 A KR20240016938 A KR 20240016938A KR 1020237029259 A KR1020237029259 A KR 1020237029259A KR 20237029259 A KR20237029259 A KR 20237029259A KR 20240016938 A KR20240016938 A KR 20240016938A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- compound
- morpholino
- group
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163144287P | 2021-02-01 | 2021-02-01 | |
| US63/144,287 | 2021-02-01 | ||
| PCT/US2022/013725 WO2022164812A1 (en) | 2021-02-01 | 2022-01-25 | Phosphoinositide 3 kinase beta inhibitors and compositions and methods thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240016938A true KR20240016938A (ko) | 2024-02-06 |
Family
ID=82654889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237029259A Pending KR20240016938A (ko) | 2021-02-01 | 2022-01-25 | 포스포이노시티드 3 키나아제 베타 억제제 및 그 조성물 및 방법 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240166617A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4284375A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024508045A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240016938A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117615763A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022214080A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3209581A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL304895A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022164812A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3217937A1 (en) | 2021-05-03 | 2022-11-10 | Erin Danielle ANDERSON | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease |
| MX2023013987A (es) | 2021-05-27 | 2024-02-12 | Petra Pharma Corp | Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento contra el cáncer. |
| TW202329930A (zh) | 2021-09-30 | 2023-08-01 | 美商佩特拉製藥公司 | 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑 |
| US20260130925A1 (en) * | 2022-10-14 | 2026-05-14 | Genesis Molecular Ai, Inc. | Methods for treating cancer |
| EP4602043A1 (en) * | 2022-10-14 | 2025-08-20 | Genesis Therapeutics, Inc. | 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer |
| EP4680612A1 (en) * | 2023-03-15 | 2026-01-21 | AN2 Therapeutics, Inc. | Chemical compounds |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE363471T1 (de) * | 2000-01-24 | 2007-06-15 | Astrazeneca Ab | Durch einen morpholinrest substituierte therapeutische verbindungen |
| EP1537102A4 (en) * | 2002-08-16 | 2010-12-08 | Astrazeneca Ab | INHIBITORS OF PHOSPHOINOSITIDE-3-KINASE BETA |
| WO2008148074A2 (en) * | 2007-05-24 | 2008-12-04 | Research Foundation Of State University Of New York | Inhibitors of mtor and methods of treatment using same |
| US8399460B2 (en) * | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
-
2022
- 2022-01-25 CN CN202280017243.9A patent/CN117615763A/zh active Pending
- 2022-01-25 EP EP22746472.4A patent/EP4284375A4/en active Pending
- 2022-01-25 WO PCT/US2022/013725 patent/WO2022164812A1/en not_active Ceased
- 2022-01-25 IL IL304895A patent/IL304895A/en unknown
- 2022-01-25 CA CA3209581A patent/CA3209581A1/en active Pending
- 2022-01-25 JP JP2023571435A patent/JP2024508045A/ja active Pending
- 2022-01-25 KR KR1020237029259A patent/KR20240016938A/ko active Pending
- 2022-01-25 US US18/273,634 patent/US20240166617A1/en active Pending
- 2022-01-25 AU AU2022214080A patent/AU2022214080A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022164812A1 (en) | 2022-08-04 |
| US20240166617A1 (en) | 2024-05-23 |
| CA3209581A1 (en) | 2022-08-04 |
| AU2022214080A1 (en) | 2023-09-14 |
| EP4284375A1 (en) | 2023-12-06 |
| CN117615763A (zh) | 2024-02-27 |
| IL304895A (en) | 2023-10-01 |
| JP2024508045A (ja) | 2024-02-21 |
| EP4284375A4 (en) | 2025-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2023061294A1 (zh) | 含氮杂环类衍生物调节剂、其制备方法及应用 | |
| JP5766820B2 (ja) | Pi3キナーゼ阻害剤としての複素環化合物 | |
| JP6819585B2 (ja) | Brk阻害化合物 | |
| CN104918934B (zh) | 3‑取代的吡唑及其作为dlk抑制剂的用途 | |
| TW202328124A (zh) | 1,4-氧雜氮雜環庚烷衍生物及其用途 | |
| CN120092011A (zh) | Kras g12d抑制剂 | |
| WO2021121397A1 (zh) | 取代的炔基杂环化合物 | |
| WO2020108590A1 (zh) | 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用 | |
| KR20240127910A (ko) | Sos1 억제제 및 항암제를 포함하는 암 치료용 약학 조성물 | |
| WO2022164812A1 (en) | Phosphoinositide 3 kinase beta inhibitors and compositions and methods thereof | |
| CN108349996B (zh) | 三环pi3k抑制剂化合物及其使用方法 | |
| CN110520416B (zh) | 多取代吡啶酮类衍生物、其制备方法及其医药用途 | |
| US11370792B2 (en) | Caffeine inhibitors of MTHFD2 and uses thereof | |
| TW202116774A (zh) | 炔類衍生物及其製備方法和用途 | |
| CN115867346A (zh) | 激酶抑制剂 | |
| KR20200090636A (ko) | 피롤로피리미딘 유도체 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 | |
| TW202233190A (zh) | 作為PI3Kδ抑制劑的咪唑並[1,5-A]吡衍生物 | |
| WO2020233645A1 (zh) | 大环类衍生物、及其制备方法和用途 | |
| CN116964046B (zh) | Plk4抑制剂及其用途 | |
| CN115677682B (zh) | 螺环类plk4抑制剂及其用途 | |
| WO2023036289A1 (zh) | 具有enpp1抑制活性的异羟基肟酸类化合物及其用途 | |
| WO2022166796A1 (zh) | 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途 | |
| WO2023143282A1 (zh) | 含有肼基的化合物 | |
| CN113754685B (zh) | 二氢硫代色烯并吡唑类衍生物、其制备方法及其在医药上的应用 | |
| CN116514817A (zh) | 具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |